<DOC>
	<DOCNO>NCT02080234</DOCNO>
	<brief_summary>To evaluate efficacy safety first-line gemcitabine , oxaliplatin , asparaginase ( GELOX ) concurrent involved-field radiation therapy patient newly diagnose stage IE/IIE ENKTL .</brief_summary>
	<brief_title>Combine GELOX With Concurrent Radiation Therapy Patients With Stage IE/IIE ENKTL</brief_title>
	<detailed_description>1 . Patients - All patient sign write informed consent form enrollment , study approve Sun Yat-sen University Cancer Center Ethics Board . - Baseline patient : Computed tomography ( CT ) scan chest , abdomen , pelvis , magnetic resonance image study head neck , bilateral bone marrow aspiration biopsy . Positron emission tomography-CT scan ( optional ) . Epstein-Barr virus ( E B V ) DNA blood level , titer EBV antibody ( EA-IgA , VCA-IgA ) , β2-micro globulin ( β2-MG ) soluble CD 25 ( sCD 25 ) serum . - Recheck every course : Epstein-Barr virus ( EBV ) DNA blood level , titer EBV antibody ( EA-IgA , VCA-IgA ) , β2-micro globulin ( β2-MG ) soluble CD 25 ( sCD25 ) serum . - Recheck every two course : Computed tomography ( CT ) scan chest , abdomen , pelvis , magnetic resonance image study head neck , bilateral bone marrow aspiration biopsy . Positron emission tomography-CT scan ( optional ) 2 . Treatment Protocol - The GELOX regimen consist follow drug : gemcitabine ：1250 mg/ m2 day 1 , ivdrip oxaliplatin ：85 mg/m2 day 1 , ivdrip pegaspargase : 2500 IU/m 2 daily day 1 , intramuscular The treatment cycle repeat every 14 day . - IFRT deliver use 6-MeV linear accelerator use 3-dimensional conformable treatment planning . The IFRT dose 56 gray ( Gy ) 28 fraction , define clinical target volume limited stage IE disease bilateral nasal cavity , bilateral ethmoid sinus , ipsilateral maxillary sinus ; clinical target volume would extend involved tissue patient extensive stage IE disease . For patient stage IIE disease , clinical target volume also , include bilateral cervical lymph node area . - Disease Progression treatment treat second-line therapy .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<criteria>newly diagnose ENKTL age:1869years Ann Arbor stage IE , stage IIE cervical lymph node involvement lease one measurable lesion receive chemotherapy radiotherapy Eastern CooperativeOncology Group performance status 0 2 . Adequate hematologic function ( eg , white blood cell ≥ 3×10e9/l , neutrophil count ≥1.5×10e9/L , platelet count≥ 100×10e9/L ) , renal function ( eg , serum creatinine≤1.5 mg/dL creatinine clearance ≥50 mL minute ) , hepatic function ( e.g , total bilirubin≤ 2 time upper limit normal aspartate alanine transaminase level ≤ 3 time upper limit normal ) mismatch inclusion criterion systematic central nervous system involvement , previous concomitant malignancy coexist medical problem could cause poor compliance study protocol . primary lesion upper respiratory</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Lymphoma , Extranodal NK-T-Cell</keyword>
	<keyword>asparaginase</keyword>
	<keyword>GELOX</keyword>
	<keyword>concurrent chemoradiotherapy</keyword>
	<keyword>sIL-2R</keyword>
</DOC>